Pluri Inc.

Pluri Inc. is a biotechnology company that researches, develops, and manufactures cell-based products, cell therapeutics, and related technologies for various industries. Its pipeline includes placenta-based cell therapy candidates such as PLX-PAD for inflammatory and muscle injuries and hematologic conditions, and PLX-R18 for hematopoietic complications. The company also offers cell manufacturing services, cell-based coffee, and cultivated meat products, and operates in regenerative medicine, food tech, immunotherapy, and CDMO services through its PluriCDMO division. Formerly known as Pluristem Therapeutics Inc., it changed its name to Pluri Inc. in July 2022, was incorporated in 2001, and is based in Haifa, Israel.